|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells.
|
15750627 |
2005 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Two ETS transcription factors, ERG and ETV1, were identified as outliers in prostate cancer.
|
16254181 |
2005 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
|
16820092 |
2006 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement.
|
16951139 |
2006 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, both the isoforms of TMPRSS2/ERG fusions expressed and expression level may affect prostate cancer progression.
|
16951141 |
2006 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.
|
17059688 |
2006 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, our data indicate that the TMPRSS2:ERG translocation is common in advanced prostate cancer and occurs by virtue of unbalanced genomic rearrangements.
|
17079440 |
2006 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
|
17108102 |
2006 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among the genes most consistently and highly upregulated in prostate cancer was the ETS family transcription factor ERG (ETS related gene).
|
17143509 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assayed for the presence of the TMPRSS2:ERG gene fusion product among 26 patients who underwent surgery for clinically localized prostate cancer using RT-PCR and direct DNA sequencing, and evaluated its prognostic significance.
|
17172822 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
|
17237811 |
2007 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, we define a novel approach to study these gene fusions and identified cases where TMPRSS2 was rearranged without rearrangement of ERG, ETV1 or ETV4 and cases with ETS family gene rearrangement without TMPRSS2 rearrangement, suggesting that novel 5' and 3' partners may be involved in gene fusions in prostate cancer.
|
17334343 |
2007 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nonetheless, the discovery of a novel variant TMPRSS2 isoform-ERG fusion adds to the characterization of ETS-family rearrangements in prostate cancer, and has important implications for the accurate molecular diagnosis of TMPRSS2-ETS fusions.
|
17334351 |
2007 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five morphological features were associated with TMPRSS2-ERG fusion prostate cancer: blue-tinged mucin, cribriform growth pattern, macronucleoli, intraductal tumour spread, and signet-ring cell features, all with p-values < 0.05.
|
17385188 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that ERG gene fusions might be of prognostic significance in prostate cancer.
|
17390040 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer.
|
17401460 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
|
17527075 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators.
|
17637754 |
2008 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence/absence of Alu family consensus sequence in the introns of TMPRSS2 and ERG correlates with the presence/absence of fusion transcripts of theses two genes, indicating that these consensus sequences may contribute to genomic deletions and the fusion of TMPRSS2 and ERG in prostate cancer.
|
17654723 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we used for the first time the combination of the prostate cancer-specific biomarkers TMPRSS2-ERG and PCA3, which significantly improves the sensitivity for prostate cancer diagnosis.
|
17785564 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a survival analysis to determine the prognostic significance of the presence of the TMPRSS2:ERG fusion gene on the risk of prostate cancer recurrence, adjusting for the established prognostic factors.
|
17971772 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors.
|
17991527 |
2007 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer.
|
18065961 |
2008 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.
|
18165275 |
2008 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We propose that up-regulation of ERG in human prostate cancer activates cell invasion programs that subsequently displace basal cells by neoplastic epithelium.
|
18245377 |
2008 |